Myasthenia gravis trials in Canada
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Montreal
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - Phase 3Taking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Montreal, Ottawa, Toronto
- Age
- 18 years and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - Phase 2/3Enrolling by invitationEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Calgary, Ottawa
- Age
- 2 years to 18 years
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - Phase 3Taking peopleEfgartigimod in IVIG Dependent Myasthenia Gravis Patients
- Where
- Gatineau
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Clinique Neuro-Outaouais
See details and how to joinNCT06765161 - Phase 3Taking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Burnaby
- Age
- 18 years and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - Phase 1Taking peopleStudy of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
- Where
- Montreal, Ottawa
- Age
- 18 years to 75 years
- People
- 57 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07304154 - Phase 2/3Taking peopleA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Ottawa
- Age
- 2 years to 17 years
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - No phaseTaking peopleRegistry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Where
- Brampton, London, Montreal
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341